FDA Authorizes Novavax’s Covid-19 Vaccine

U.S. health regulators have authorized the use of Novavax Inc.’s Covid-19 vaccine, providing a new option that works differently than the two leading vaccines, but at a time when overall demand for vaccines and boosters is low. The Food and Drug Administration said Wednesday that adults 18 years and older may receive Novavax’s vaccine. The Novavax vaccine, given as two doses three weeks apart, could become available soon if the Centers for Disease Control and Prevention signs off in the coming days. The authorization gives adults “another option that meets the FDA’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency-use authorization,” FDA Commissioner Robert M. Califf said.